Eudaimonia Partners’s AbbVie ABBV Stock Holding History

Eudaimonia Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$657K	Sell	3,609 -207	-5%	-$35.7K	0.16%	137
2023 Q4	$591K	Buy	+3,816	New	+$556K	0.15%	135
2023 Q3	–	Sell	-5,991	Closed	-$807K	–	329
2023 Q2	$807K	Buy	5,991 +410	+7%	+$60.1K	0.18%	131
2023 Q1	$889K	Sell	5,581 -5,481	-50%	-$838K	0.21%	111
2022 Q4	$1.79M	Sell	11,062 -3,050	-22%	-$468K	0.44%	56
2022 Q3	$1.89M	Sell	14,112 -11,950	-46%	-$1.71M	0.49%	50
2022 Q2	$3.99M	Sell	26,062 -37	-0.1%	-$5.65K	0.73%	33
2022 Q1	$4.23M	Buy	+26,099	New	+$3.79M	0.72%	27
2021 Q3	$2.34M	Sell	21,729 -1,469	-6%	-$168K	0.42%	68
2021 Q2	$2.61M	Buy	23,198 +3,091	+15%	+$348K	0.49%	52
2021 Q1	$2.18M	Sell	20,107 -1,882	-9%	-$201K	0.45%	55
2020 Q4	$2.36M	Sell	21,989 -270	-1%	-$25.9K	0.53%	50
2020 Q3	$1.95M	Sell	22,259 -2,072	-9%	-$195K	0.5%	52
2020 Q2	$2.39M	Buy	24,331 +1,223	+5%	+$108K	0.91%	26
2020 Q1	$1.76M	Buy	23,108 +4,918	+27%	+$419K	0.77%	31
2019 Q4	$1.61M	Buy	+18,190	New	+$1.51M	0.64%	40

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Eudaimonia Partners's ABBV Position: Q1 2024 in Review

Eudaimonia Partners reduced its AbbVie (ABBV) stake by 5.4% in Q1 2024, selling an estimated $35.7K and leaving 3,609 shares worth $657K. The position accounts for 0.16% of the portfolio, ranked #137.

Eudaimonia Partners first reported a position in ABBV in Q4 2019 and has held it in 16 quarters since. The position peaked at $4.23M in Q1 2022. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Eudaimonia Partners held 3,609 shares of AbbVie worth $657K as of Q1 2024.
Eudaimonia Partners sold 207 AbbVie shares in Q1 2024, an estimated $35.7K.
AbbVie made up 0.16% of Eudaimonia Partners's portfolio in Q1 2024, its #137 holding.
Eudaimonia Partners first reported a position in AbbVie in Q4 2019 and has held it in 16 quarters since.
Eudaimonia Partners's AbbVie position peaked at $4.23M in Q1 2022.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Eudaimonia Partners's 13F filing for Q1 2024, filed 25 Apr 2024.